Cardiology

Expansion of the original 2015 approval makes Praluent a strong lipid-lowering candidate for patients with diabetes and other cardiovascular concerns.

The face of heart disease is changing in the U.S., and obesity and diabetes may be key factors.

Is one more important than the other?

Another medication taken for type 2 diabetes may also help reverse a potentially life-threatening heart condition.

To date, there is limited evidence concerning the potential health benefits of eating nuts for persons with T2D.

Could the most inexpensive treatment for arterial stiffness be a healthy walk?

Featuring exclusive comments from Dr. George Bakris
Studies are rarely stopped early; when it happens, we should take notice of the results.

GLP1-RA and SGLT2i reduce atherosclerotic major cardiovascular events (MACE) to a similar degree in patients with established ASCVD.

Metformin may help lower the risk of cardiovascular events and death in patients with moderate to severe renal function.

This may not be an actual “physical” disaster averted yet because we don’t know the long-term effects on the people who have taken the ARBs and possibly other medications that were tainted with carcinogens or other “poisons.” When we (health care providers) were first notified of this issue, my first …